Development
Biodesix, Inc.
BDSX
$0.3029
$0.02117.49%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 8.72% | 13.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.72% | 13.64% | |||
| Cost of Revenue | 4.49% | -0.28% | |||
| Gross Profit | 10.06% | 18.86% | |||
| SG&A Expenses | 4.87% | -6.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.12% | -9.37% | |||
| Operating Income | 4.55% | 34.36% | |||
| Income Before Tax | 16.53% | 18.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.53% | 18.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.53% | 18.02% | |||
| EBIT | 4.55% | 34.36% | |||
| EBITDA | 8.15% | 37.00% | |||
| EPS Basic | 27.95% | 19.22% | |||
| Normalized Basic EPS | 28.17% | 19.19% | |||
| EPS Diluted | 27.95% | 19.22% | |||
| Normalized Diluted EPS | 28.17% | 19.19% | |||
| Average Basic Shares Outstanding | 15.83% | 1.53% | |||
| Average Diluted Shares Outstanding | 15.83% | 1.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||